Dendritic cell costimulatory molecule expression and immunosuppressant intervention

doi:10.3969/j.issn.2095-4344.2015.24.020

Abstract

Abstract:

BACKGROUND: Previous studies on immunosuppression and anti-rejection after organ

transplantation mainly focused on effects of T lymphocytes-mediated immune response

and immunosuppressive agents on T lymphocytes. Effects of dendritic cells were

unclear. The manifestation and mechanism of immunosuppressive agent effects on

dendritic cells are not identical.
OBJECTIVE: To compare the effects of different immunosuppressive agents on

expression and function of costimulatory molecules of dendritic cells, and to

explore the mechanism of action of immunosuppressive agents.
METHODS: 20 μg/L rapamycin, 0.04 mg/L mycophenolate, 10 μg/L tacrolimus and 1 mg/L

cyclosporine A were separately added during bone marrow cells of C57BL/6 mice were

differentiated into dendritic cells.
RESULTS AND CONCLUSION: Flow cytometry results revealed that CD40 expression in each

group: rapamycin < tacrolimus < cyclosporine A < mycophenolate mofetil (P < 0.01);

CD86 expression: rapamycin < tacrolimus < cyclosporine A = mycophenolate mofetil (P

< 0.01). There was no significant difference in CD80, CD11c and major

histocompatibility complex II expression among groups (P > 0.05). One-way mixed

lymphocyte reaction results displayed dendritic cell costimulatory T cell proliferation in each group:

rapamycin < mycophenolate mofetil < tacrolimus = cyclosporine A (P < 0.05). The

results confirmed that rapamycin, tacrolimus, cyclosporine A, and mycophenolate

mofetil exerted immunosuppression by suppressing CD40 and CD86, especially

rapamycin. Above medicines do not noticeably inhibit major histocompatibility

complex II expression, but suppress T cell proliferation, and the inhibitory effect

of rapamycin on cell proliferation is strongest.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Tissue Engineering, Dendrites, Rapamycin, Lymphocytes

CLC Number:

R318

Yang Xiao-yong, Yao Qing-chun, Wang Wei, Qi Man, Hong Xi-ying, Liu Chen-mei, Yin Hang, Liu Hang, Ren Liang, Hu Xiao-peng, Zhang Xiao-dong. Dendritic cell costimulatory molecule expression and immunosuppressant intervention[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(24): 3876-3881.

References

[1] Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142-1162.
[2] Mackern-Oberti JP, Llanos C, Vega F, et al. Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases. Autoimmun Rev. 2015;14(2):127-139.
[3] Park MJ, Park KS, Park HS, et al. A distinct tolerogenic subset of splenic IDO(+)CD11b(+) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collagen-induced arthritis. Cell Immunol. 2012;278(1-2):45-54.
[4] Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature. 2011;479(7374):542-546.
[5] Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation: how much of the promise has been realized? Nat Med. 2005;11:605-613.
[6] Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7: 610-621.
[7] Inaba K, Swiggard WJ, Steinman RM, et al. Isolation of dendritic cells. Curr Protoc Immunol, 2009; chapter 3, Unit 3.7.
[8] Matsue H, Yang C, Matsue K, et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol. 2002; 169(7):3555-3564.
[9] Morel PA, Butterfield LH. Dendritic cell control of immune responses. Front Immunol. 2015;6:42.
[10] Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int. 2011;24(1):2-11.
[11] Vogel I, Kasran A, Cremer J, et al. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity. Eurol J Immunol. 2015.
[12] Sharpe AH, Freeman G J. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116-126.
[13] Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol, 2015;16(4):343-353.
[14] Ribot JC, Debarros A, Mancio-Silva L, et al. B7-CD28 costimulatory signals control the survival and proliferation of murine and human γδ T cells via IL-2 production. J Immunol. 2012;189(3):1202-1208.
[15] Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin- conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178(11):7018-7031.
[16] Macedo C, Turquist H, Metes D, et al. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res. 2012;28(1):16.
[17] Zaccard CR, Watkins SC, Kalinski P,et al. CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity. J Immunol. 2015;294(3):1047-1056.
[18] Woltman AM, de Fijter JW, Kamerling SW, et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol. 2000;30(7): 1807- 1812.
[19] Lee JI, Ganster RW, Geller DA, et al. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation. 1999;68(9):1255-1263.
[20] Dupuy P, Bagot M, Michel L, et al. Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol. 1991;96(4):408- 413.
[21] Varey AM, Champion BR, Cooke A. Cyclosporine affects the function of antigen-presenting cells. Immunology. 1986;57(1): 111-114.
[22] Roberts MS, Knight SC. Low-dose immunosuppression by cyclosporine operating via antigen-presenting dendritic cells. Transplantation. 1990;50(1):91-95.
[23] Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med. 2001;49(5):442-449.
[24] Lee SJ, Song L, Yang MC, et al. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Vaccine. 2015;33(13):1549-55.
[25] Amiel E, Everts B, Fritz D, et al. Mechanistic target of rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function. J Immunol. 2014;193(6): 2821-2830.
[26] Chiang PH, Wang L, Liang Y, et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic cell function. Transplant Proc. 2002;34(5): 1394-1395.
[27] Coates PT, Colvin BL, Kaneko K, et al. Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation. 2003;75(9 Suppl):32S-36S.
[28] Lee YR, Yang IH, Lee YH, et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood. 2005;105(10): 3951-3955.
[29] Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165(5):2374-2381.
[30] Cicinnati VR, Hou J, Lindemann M, et al. Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells. Transplantation. 2009;88(4):504-513.
[31] Kambayashi T, Wallin RP, Ljunggren HG. cAMP-elevating agents suppress dendritic cell function. J Leukoc Biol. 2001; 70(6):903-910.